The drug with INN sacubitrile/valsartan (Juperio) of Novartis was approved by the Ministry of Health of Russia for the treatment of essential arterial hypertension. This is stated in the press release of the company. Registration is based on data from 13 international clinical studies with participation of about 7,000 AG patients (including from Russia) taking Juperio 12 weeks to 1 year in doses of 200 or 400 mg once a day. Research data demonstrated the advantage of Juperio therapy in lowering blood pressure compared to therapy with angiotensin II receptor antagonists (APA II) with comparable safety.
NEW ARTICLES
